title: Characterization of Poliovirus Neutralization Escape Mutants of Single-Domain Antibody Fragments (VHHs).
abstract: To complete the eradication of poliovirus and to protect unvaccinated people subsequently, the development of one or more antiviral drugs will be necessary. A set of five single-domain antibody fragments (variable parts of the heavy chain of a heavy-chain antibody [VHHs]) with an in vitro neutralizing activity against poliovirus type 1 was developed previously (B. Thys, L. Schotte, S. Muyldermans, U. Wernery, G. Hassanzadeh-Ghassabeh, and B. Rombaut, Antiviral Res 87:257-264, 2010, http://dx.doi.org/10.1016/j.antiviral.2010.05.012), and their mechanisms of action have been studied (L. Schotte, M. Strauss, B. Thys, H. Halewyck, D. J. Filman, M. Bostina, J. M. Hogle, and B. Rombaut, J Virol 88:4403-4413, 2014, http://dx.doi.org/10.1128/JVI.03402-13). In this study, neutralization escape mutants were selected for each VHH. Sequencing of the P1 region of the genome showed that amino acid substitutions are found in the four viral proteins of the capsid and that they are located both in proximity to the binding sites of the VHHs and in regions further away from the canyon and hidden beneath the surface. Characterization of the mutants demonstrated that they have single-cycle replication kinetics that are similar to those of their parental strain and that they are all drug (VHH) independent. Their resistant phenotypes are stable, as they do not regain full susceptibility to the VHH after passage over HeLa cells in the absence of VHH. They are all at least as stable as the parental strain against heat inactivation at 44°C, and three of them are even significantly (P < 0.05) more resistant to heat inactivation. The resistant variants all still can be neutralized by at least two other VHHs and retain full susceptibility to pirodavir and 35-1F4.
authors.affiliation: Department of Pharmaceutical Biotechnology and Molecular Biology, Center for Neurosciences, Vrije Universiteit Brussel, Brussels, Belgium.
authors.forename: Lise
authors.initials: L
authors.lastname: Schotte
authors.affiliation: Department of Pharmaceutical Biotechnology and Molecular Biology, Center for Neurosciences, Vrije Universiteit Brussel, Brussels, Belgium.
authors.forename: Bert
authors.initials: B
authors.lastname: Thys
authors.affiliation: Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA.
authors.forename: Mike
authors.initials: M
authors.lastname: Strauss
authors.affiliation: Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA.
authors.forename: David J
authors.initials: DJ
authors.lastname: Filman
authors.affiliation: Department of Pharmaceutical Biotechnology and Molecular Biology, Center for Neurosciences, Vrije Universiteit Brussel, Brussels, Belgium.
authors.forename: Bart
authors.initials: B
authors.lastname: Rombaut
authors.affiliation: Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA james_hogle@hms.harvard.edu.
authors.forename: James M
authors.initials: JM
authors.lastname: Hogle
mesh_terms: D019943:Amino Acid Substitution / Q000276:immunology; D057134:Antibodies, Neutralizing / Q000276:immunology*; D000998:Antiviral Agents / Q000494:pharmacology; D001665:Binding Sites / Q000276:immunology; D036022:Capsid Proteins / Q000276:immunology; D045744:Cell Line, Tumor; D006367:HeLa Cells; D006801:Humans; D007128:Immunoglobulin Fragments / Q000276:immunology*; D009154:Mutation / Q000276:immunology*; D017955:Poliovirus / Q000187:drug effects / Q000276:immunology*; D014764:Viral Proteins / Q000276:immunology
chemical_list: D057134:Antibodies, Neutralizing; D000998:Antiviral Agents; D036022:Capsid Proteins; D007128:Immunoglobulin Fragments; D014764:Viral Proteins